EA202190201A1 - Составы для уменьшения размера опухоли и способы их применения - Google Patents

Составы для уменьшения размера опухоли и способы их применения

Info

Publication number
EA202190201A1
EA202190201A1 EA202190201A EA202190201A EA202190201A1 EA 202190201 A1 EA202190201 A1 EA 202190201A1 EA 202190201 A EA202190201 A EA 202190201A EA 202190201 A EA202190201 A EA 202190201A EA 202190201 A1 EA202190201 A1 EA 202190201A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
tumor size
application
size reduction
Prior art date
Application number
EA202190201A
Other languages
English (en)
Inventor
Стивен Хоффман
Джон Ротман
Original Assignee
Тайм, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайм, Инк filed Critical Тайм, Инк
Publication of EA202190201A1 publication Critical patent/EA202190201A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к композициям и способам уменьшения размера опухоли. В частности, изобретение относится к композициям, содержащим комбинацию склерозирующего агента и агента, усиливающего проницаемость.
EA202190201A 2018-07-09 2019-07-02 Составы для уменьшения размера опухоли и способы их применения EA202190201A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202190201A1 true EA202190201A1 (ru) 2021-04-09

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190201A EA202190201A1 (ru) 2018-07-09 2019-07-02 Составы для уменьшения размера опухоли и способы их применения

Country Status (11)

Country Link
EP (1) EP3820482A4 (ru)
JP (1) JP2021530482A (ru)
KR (1) KR20220098082A (ru)
CN (1) CN112584841A (ru)
AU (1) AU2019309757A1 (ru)
BR (1) BR112021000279A8 (ru)
CA (1) CA3105717A1 (ru)
EA (1) EA202190201A1 (ru)
IL (1) IL280000A (ru)
PH (1) PH12021550033A1 (ru)
WO (1) WO2020023191A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202193111A1 (ru) 2019-05-14 2022-02-10 Тайм, Инк. Композиции и способы для лечения рака
AU2020401131A1 (en) * 2019-12-09 2022-07-14 Tyme, Inc. Pharmaceutical compositions and methods
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005209243A1 (en) * 2004-01-29 2005-08-11 Baxter Healthcare S.A. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
EP3169707B1 (en) * 2014-07-11 2020-12-02 The Regents of the University of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
CN109195601A (zh) * 2016-03-15 2019-01-11 迪美公司 用于治疗癌症的药物组合物

Also Published As

Publication number Publication date
BR112021000279A8 (pt) 2021-04-20
KR20220098082A (ko) 2022-07-11
AU2019309757A1 (en) 2021-03-04
BR112021000279A2 (pt) 2021-04-06
EP3820482A4 (en) 2022-03-23
IL280000A (en) 2021-03-01
CA3105717A1 (en) 2020-01-30
JP2021530482A (ja) 2021-11-11
EP3820482A1 (en) 2021-05-19
CN112584841A8 (zh) 2021-06-18
WO2020023191A1 (en) 2020-01-30
PH12021550033A1 (en) 2021-09-20
CN112584841A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201890754A1 (ru) Соединения и способы их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201590997A1 (ru) Соединения и способы их применения
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA202090183A1 (ru) Композиции, способы и получение дейтерированного домперидона
EA202190201A1 (ru) Составы для уменьшения размера опухоли и способы их применения
MX2017011521A (es) Composiciones topicas que comprenden un corticosteroide.
EA201791174A1 (ru) Антимикотическое соединение
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA201990978A1 (ru) Антитела против pd-1
EA201691896A1 (ru) Соединения и способы их применения
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений